Vepacel

RSS

Prepandemic influenza vaccine (H5N1) (whole virion, inactivated,prepared in cell culture)

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Vepacel has been withdrawn at the request of the marketing authorisation holder.

This EPAR was last updated on 28/10/2020

Authorisation details

Product details
Name
Vepacel
Agency product number
EMEA/H/C/002089
Active substance
Influenza virus (whole virion, inactivated), containing antigen of: A/Vietnam/1203/2004 (H5N1)
International non-proprietary name (INN) or common name
Prepandemic influenza vaccine (H5N1) (whole virion, inactivated,prepared in cell culture)
Therapeutic area (MeSH)
  • Influenza, Human
  • Immunization
  • Disease Outbreaks
Anatomical therapeutic chemical (ATC) code
J07BB01
Publication details
Marketing-authorisation holder
Ology Bioservices Ireland LTD
Revision
9
Date of issue of marketing authorisation valid throughout the European Union
17/02/2012
Contact address

2 Shelbourne Buildings
Crampton Avenue
Dublin 4
D04 W346
Ireland

Product information

11/01/2019 Vepacel - EMEA/H/C/002089 - T/0019

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Influenza vaccines

Therapeutic indication

Active immunisation against H5N1 subtype of influenza A virus.

This indication is based on immunogenicity data from subjects from the age of 6 months onwards following administration of two doses of vaccine prepared with H5N1 subtype strains.

Vepacel should be used in accordance with Official guidance.

Assessment history

How useful was this page?

Add your rating
Average
11 ratings
2 ratings
11 ratings
8 ratings